Certara, Inc. (NASDAQ:CERT) Shares Bought by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC raised its holdings in Certara, Inc. (NASDAQ:CERT) by 8.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 810,206 shares of the company’s stock after purchasing an additional 62,912 shares during the period. Kayne Anderson Rudnick Investment Management LLC owned 0.50% of Certara worth $11,221,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of CERT. Blue Trust Inc. purchased a new stake in shares of Certara in the second quarter valued at about $26,000. Pineridge Advisors LLC purchased a new position in shares of Certara during the fourth quarter valued at approximately $28,000. Innealta Capital LLC purchased a new position in shares of Certara during the second quarter valued at approximately $36,000. YHB Investment Advisors Inc. purchased a new position in shares of Certara during the first quarter valued at approximately $47,000. Finally, Intech Investment Management LLC purchased a new position in shares of Certara during the second quarter valued at approximately $152,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Insider Activity at Certara

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.39% of the company’s stock.

Certara Price Performance

CERT opened at $10.90 on Monday. The company has a fifty day simple moving average of $13.26 and a 200 day simple moving average of $15.37. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -27.95, a PEG ratio of 5.23 and a beta of 1.49. Certara, Inc. has a twelve month low of $10.35 and a twelve month high of $19.87. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The firm had revenue of $93.31 million for the quarter, compared to analyst estimates of $96.01 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. Certara’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 earnings per share. Equities research analysts expect that Certara, Inc. will post 0.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Barclays reduced their price objective on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. UBS Group cut their price target on shares of Certara from $20.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. KeyCorp cut their price target on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, Robert W. Baird dropped their price objective on shares of Certara from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Seven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $17.79.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.